Evidence map›Paper›PMID 38912335›Full record

ArticleFrontiers in medicine2024

The hospitalization burden of inflammatory bowel disease in a southwestern highland region of China: a territory-wide study from 2015 to 2020.

Yan Tao, Maojuan Li, Huabin Gao, Yang Sun, Fengrui Zhang, Jing Wu, Hao Liang, Liping He, Min Gong, Junkun Niu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yan Tao *Department of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Maojuan Li *Department of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Huabin GaoYunnan Evaluation Center for Medical Service and Administration, Kunming, Yunnan, China.
Yang SunDepartment of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Fengrui ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Jing WuDepartment of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Hao LiangDepartment of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Liping HeSchool of Public Health, Kunming Medical University, Kunming, Yunnan, China.
Min GongDepartment of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Junkun NiuDepartment of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Yinglei MiaoDepartment of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Yunnan, a southwest highland and newly industrialized region of China, has an unknown hospitalization burden of inflammatory bowel disease (IBD). The study was conducted to explore territorial hospitalization burden of IBD. Methods: The formatted medical records of patients with IBD were collected from a territory-wide database in Yunnan Province, China, from 2015 to 2020. General characteristics of the study population were reported using descriptive statistics. To evaluate the length of stay, hospitalization costs, surgery, complications, and trends in patients with inflammatory bowel disease. The logistic regression analysis was established to explore the factors affecting the hospitalization costs. Results: A total of 12,174 records from 8192 patients were included. The annual hospitalization cost of IBD in Yunnan Province increased significantly from 2015 to 2020. From 2015 to 2020, the regional hospitalization burden of IBD increased, but it represented a decline in cost per hospitalization ( Conclusion: The increasing burden of IBD is noteworthy a newly industrialized region of China. Interventions targeting surgery, complications, and comorbidities may be effective means of controlling the increasing hospitalization costs of IBD in the regions.

Indexed as

comorbiditiesCrohn’s diseasehospitalization costsinflammatory bowel diseaseulcerative colitis

Identifiers

PMID38912335
PMCPMC11190343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.